KemPharm gets notice of allowance from USPTO for NME prodrug of methylphenidate
The application covers composition of matter for KP415, the company’s NME prodrug of methylphenidate. KP415 is designed to be a controlled release (CR), abuse-deterrent methylphenidate product and is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.